Trisha Piontek

1.3k total citations
12 papers, 339 citations indexed

About

Trisha Piontek is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Trisha Piontek has authored 12 papers receiving a total of 339 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Hematology, 6 papers in Molecular Biology and 5 papers in Oncology. Recurrent topics in Trisha Piontek's work include Multiple Myeloma Research and Treatments (11 papers), Peptidase Inhibition and Analysis (5 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). Trisha Piontek is often cited by papers focused on Multiple Myeloma Research and Treatments (11 papers), Peptidase Inhibition and Analysis (5 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). Trisha Piontek collaborates with scholars based in United States, United Kingdom and France. Trisha Piontek's co-authors include January Baron, Ira Gupta, Sagar Lonial, Ashraf Badros, Ajay K. Nooka, Douglas W. Sborov, Natalie S. Callander, Julie Byrne, Joanna Opalinska and Rakesh Popat and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Trisha Piontek

12 papers receiving 331 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Trisha Piontek United States 6 259 210 166 86 32 12 339
January Baron United States 7 263 1.0× 213 1.0× 171 1.0× 85 1.0× 32 1.0× 12 344
Joanna Opalińska United States 8 245 0.9× 188 0.9× 153 0.9× 90 1.0× 3 0.1× 27 284
Katarina Uttervall Sweden 8 202 0.8× 121 0.6× 122 0.7× 28 0.3× 2 0.1× 25 229
Ilaria Rizzello Italy 5 149 0.6× 96 0.5× 98 0.6× 14 0.2× 10 0.3× 23 183
Daniel Egan United States 8 127 0.5× 123 0.6× 79 0.5× 16 0.2× 3 0.1× 22 212
Anjla Sood United States 7 346 1.3× 181 0.9× 385 2.3× 11 0.1× 4 0.1× 10 476
Rayan Kaedbey Canada 6 140 0.5× 92 0.4× 96 0.6× 26 0.3× 3 0.1× 26 192
Edvan de Queiroz Crusoé Brazil 8 229 0.9× 156 0.7× 233 1.4× 7 0.1× 3 0.1× 41 353
Robin Carson United States 10 204 0.8× 160 0.8× 138 0.8× 28 0.3× 33 258
Cinnie Yentia Soekojo Singapore 10 176 0.7× 110 0.5× 202 1.2× 14 0.2× 2 0.1× 30 298

Countries citing papers authored by Trisha Piontek

Since Specialization
Citations

This map shows the geographic impact of Trisha Piontek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Trisha Piontek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Trisha Piontek more than expected).

Fields of papers citing papers by Trisha Piontek

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Trisha Piontek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Trisha Piontek. The network helps show where Trisha Piontek may publish in the future.

Co-authorship network of co-authors of Trisha Piontek

This figure shows the co-authorship network connecting the top 25 collaborators of Trisha Piontek. A scholar is included among the top collaborators of Trisha Piontek based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Trisha Piontek. Trisha Piontek is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Popat, Rakesh, Sagar Lonial, Peter M. Voorhees, et al.. (2023). Patient-Reported Outcomes With Belantamab Mafodotin Treatment in Patients With Triple-Class Refractory Multiple Myeloma. Journal of the Advanced Practitioner in Oncology. 14(6). 503–518. 3 indexed citations
2.
Lonial, Sagar, Ajay K. Nooka, Praneetha Thulasi, et al.. (2021). Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM). Blood Cancer Journal. 11(5). 103–103. 47 indexed citations
3.
4.
Lonial, Sagar, Ajay K. Nooka, Praneetha Thulasi, et al.. (2021). P-202: Characterization of ocular adverse events in patients receiving Belantamab Mafadotin for ≥12 months: post-hoc analysis of DREAMM-2 study in relapsed/refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 21. S149–S150. 1 indexed citations
5.
Farooq, Asim V., Simona Degli Esposti, Rakesh Popat, et al.. (2020). Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study. Ophthalmology and Therapy. 9(4). 889–911. 109 indexed citations
6.
Richardson, Paul G., Hans C. Lee, Adam D. Cohen, et al.. (2020). Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study. Blood Cancer Journal. 10(10). 106–106. 40 indexed citations
7.
Popat, Rakesh, Asim V. Farooq, Praneetha Thulasi, et al.. (2020). Ocular Health of Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Data from the DREAMM-2 Trial of Belantamab Mafodotin (Belamaf). Blood. 136(Supplement 1). 43–44. 2 indexed citations
8.
Nooka, Ajay K., Hans C. Lee, Ashraf Badros, et al.. (2020). Infusion-Related Reactions (IRRs) in the DREAMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). Blood. 136(Supplement 1). 22–23. 1 indexed citations
9.
Martin, Mona L., Joanna Opalińska, Trisha Piontek, et al.. (2020). Patient-Reported Experiences during and Following Treatment with Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM) in the DREAMM-2 Study. Blood. 136(Supplement 1). 1–1. 4 indexed citations
10.
11.
12.
Moreno, Víctor, Todd M. Bauer, Jon Infante, et al.. (2016). A phase I, open-label, study of GSK2879552, a lysine-specific demethylase 1 (LSD1) inhibitor, in patients with relapsed/refractory small cell lung carcinoma (SCLC). Annals of Oncology. 27. vi121–vi121. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by January Baron Breakdown of academic impact, for papers by Joanna Opalińska Breakdown of academic impact, for papers by Katarina Uttervall Breakdown of academic impact, for papers by Ilaria Rizzello Breakdown of academic impact, for papers by Daniel Egan Breakdown of academic impact, for papers by Anjla Sood Breakdown of academic impact, for papers by Rayan Kaedbey Breakdown of academic impact, for papers by Edvan de Queiroz Crusoé Breakdown of academic impact, for papers by Robin Carson Breakdown of academic impact, for papers by Cinnie Yentia Soekojo
Rankless by CCL
2026